(Q51489759)

5 April 2018

title

Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes. (English)

1 reference

5 April 2018

0 references

1 reference

Stewart MW

1

1 reference

5 April 2018

Cirkel DT

2

1 reference

5 April 2018

Furuseth K

3

1 reference

5 April 2018

Donaldson J

4

1 reference

5 April 2018

Biswas N

5

1 reference

5 April 2018

Starkie MG

6

1 reference

5 April 2018

Phenekos C

7

1 reference

5 April 2018

Hamann A

8

1 reference

5 April 2018

publication date

1 October 2006

1 reference

5 April 2018

published in

Diabetic Medicine

1 reference

5 April 2018

volume

23

1 reference

5 April 2018

issue

10

1 reference

5 April 2018

page(s)

1069-1078

1 reference

5 April 2018

Diabetic complications. The importance of glucose control

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

Evaluation of risk factors for development of complications in Type II diabetes in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

An overview of metformin in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

Earlier intervention in type 2 diabetes: the case for achieving early and sustained glycaemic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

Dyslipidaemia and cardiovascular risk in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

Diabetic dyslipidaemia: current treatment recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

Free fatty acids--do they play a central role in type 2 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

Rosiglitazone plus metformin: combination therapy for Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2006.01942.X

10.1111/J.1464-5491.2006.01942.X

21 January 2018

Identifiers

DOI

1 reference

5 April 2018

1 reference

5 April 2018